Ten weeks. Three rounds of review. Forty-seven comments still open on the document. If that sounds familiar, the problem is almost certainly not your writers, your reviewers, or the science. The problem is the process you wrapped around the content before anyone in medical, legal, or regulatory ever opened the file.
Industry benchmarks make this concrete. According to Caidera's MLR review guide, the average asset spends up to 40 days in review, with mid- to large-sized pharma companies routinely seeing 50 to 60 day cycles. The same data shows European content approval averages 20 days and 1.3 review cycles per asset, but incomplete reference packs, fragmented feedback, and unclear versioning add days or weeks every time. Veeva's research on MLR efficiency points to the same root cause: reviewers are tapped in late, without visibility into how content was created, so they end up working reactively on a rising volume of assets.
None of that is a content problem. It is a workflow problem. And it is fixable before a single reviewer is assigned.
The single biggest lever is who is in the room at the brief stage. Most teams treat medical, legal, and regulatory as approvers. The faster teams treat them as co-authors. You are not asking permission. You are removing the surprises that turn into three-week delays once the first draft lands.
A practical co-creation kickoff covers four things in one session:
This is the single intervention with the highest return. Aqurance reports that companies optimizing their MLR workflows see a 57% reduction in review cycle times and a 55% drop in time spent in review meetings. Most of that gain comes from front-loading alignment, not from speeding up the review itself.
The second lever is version discipline. The classic failure mode, well documented in industry analyses of MLR delays, is medical reviewing version 3 while legal comments on version 2 and regulatory checks version 1 in parallel. Lock versions. Route them in sequence or in a single consolidated round. Do not let the document fork.
Approved content is an asset. Most pharma teams do not treat it that way. Every new campaign starts from a blank document, which means every new campaign also starts from a blank MLR submission. That is the most expensive way to work.
A modular content repository changes the unit of review. Instead of resubmitting a full asset, you resubmit only the new components. Validated claims, approved visuals, standard safety language, and indication boilerplate live in the repository with their references, approval dates, and usage rights attached. New work assembles from these building blocks plus a smaller layer of new material.
The efficiency case is well documented. Valuebound's analysis of modular approval workflows describes one pharma company that cut a 12-week approval cycle to 3 weeks by combining modular content with embedded compliance checks. The mechanism is simple: if 70% of an asset is already approved, MLR only needs to focus on the 30% that is new. Reviewer attention is finite. Spend it on what actually needs attention.
Building the repository is a project in itself. It requires tagging, governance, a clear owner, and discipline about what gets added. But once it exists, every subsequent submission is cheaper, faster, and less risky than the one before.
Early involvement only works if reviewers have something useful to react to. Showing up to a brief with no claim hypothesis, no reference shortlist, and no format decision wastes their time and trains them to disengage.
The pattern that works in practice:
This approach was applied across multi-country rollouts Promedia has supported for brands including UCB and Bimzelx, where the cost of a late-stage objection is multiplied by every market in scope. Catching a claim issue at the brief stage costs an hour. Catching it after localization into seven markets costs weeks.
Global-first sequencing matters here too. Validate the global version, typically in English, before any local adaptation begins. Bring local medical and regulatory teams into visibility early so they know what is coming, what is locked, and what they can flex. Localization should be translation and minor market-specific adaptation. When it becomes a full rebuild in every country, the global validation work was wasted.
Reviewers spend a surprising share of their time on one task: figuring out where a statement came from and whether the reference is still valid. Anything that makes that work invisible to them adds time to the cycle.
The fix is mechanical. Pre-mark every sourced claim inside the document itself, not in a separate reference list. Include the citation, the access date, and a link or location to the source. At renewal, update last-access dates and flag any references that have moved or been superseded. This single habit removes one of the most common reasons assets bounce back in round two.
It also changes the tone of the review. Reviewers who can see your sourcing logic at a glance trust the document more. Trust shortens cycles.
A generalist agency treats MLR as a feedback round to survive. A pharma-specialist agency treats it as a quality checkpoint and builds the work backwards from it. That difference shows up in fewer review rounds, fewer compliance flags, faster approvals, and lower total cost per approved asset.
Getting it right the first time is not just better craft. It is a better commercial decision. Every avoided review round is a week of brand team time, reviewer time, and time-to-market recovered.
MLR stands for Medical, Legal, and Regulatory review. It is the internal approval process pharma companies use to check that promotional and educational content is scientifically accurate, legally defensible, and compliant with regulations governing communication about prescription medicines. Every external-facing asset, from an HCP detail aid to a patient leaflet, typically passes through MLR before it can be used.
The review itself is rarely the slow part. Delays come from incomplete reference packs, version confusion when reviewers work on different drafts in parallel, late involvement of medical and regulatory, and feedback that arrives fragmented across rounds. Industry data shows European pharma MLR cycles average around 20 days but routinely stretch to 50 or 60 at larger companies when these process issues compound.
Modular content is an approach where pharma teams build a repository of pre-approved content blocks, such as validated claims, safety language, visuals, and indication copy, each with its references and approval status attached. New campaigns assemble from these approved modules plus a smaller layer of new content, so MLR review focuses only on what is genuinely new rather than re-approving the same elements every time.
Lock the version you are submitting, attach a complete and dated reference pack, and pre-mark every sourced claim inside the document with its citation and access date. Confirm that medical, legal, and regulatory have already seen the brief and the claim direction, so the submission contains no surprises. The goal is a document a reviewer can validate without hunting for context.
If you only change one thing this quarter, change who is in the room when the brief is written. Co-creation at the brief stage removes more downstream review pain than any other single intervention, and it costs nothing except calendar discipline.
If you have budget for a second change, start scoping a modular content repository. The first submission that uses it will feel slow. The tenth will feel like a different business.
Promedia works with pharma brand and medical teams on exactly this kind of pre-MLR process design. If your current cycle is longer than it should be, the answer is almost certainly upstream of the review itself.
One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.
